Jennison Associates LLC Increases Stake in Cabaletta Bio Inc (CABA) to 11.4%

On June 4, 2026, Jennison Associates LLC filed a Schedule 13G/A with the SEC, reporting a significant increase in its stake in Cabaletta Bio Inc (CABA). As of the event date on May 29, 2026, the investment adviser beneficially owns 24,267,980 shares of common stock, representing 11.4% of the company's outstanding shares. This reflects a substantial acquisition compared to the previously reported position of approximately 8.97 million shares. Jennison Associates LLC holds sole voting power over all 24,267,980 shares but reports shared dispositive power over the same amount. The filing, which marks the fourth amendment to their original disclosure, indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Cabaletta Bio Inc is a clinical-stage biotechnology company based in Philadelphia, PA, focused on developing targeted T cell therapies for patients with autoimmune diseases.